About 135,528 results

Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Antihypertensive drugs and risk of COVID-19?
The Lancet Respiratory Medicine;

Mar 25th, 2020 - Lei Fang and colleagues1 suggest that clinicians should consider withholding angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) because of a potential increased risk of worse clinical outcomes in patients with coronavirus disease 2019 (COVID-19), and they suggest calcium channel blockers as an alternative. The hypothesis behind this suggestion is that the e...

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) inhibitors has shown promise for people with CLL, with the BTK inhibitor ibrutinib now considered a standard of care for patients of any age. However,...

PARP Inhibition Improves Outcomes in Patients With BRCA-Mutated Ovarian Cancer

May 28th, 2020 - David O'Malley, MD, professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine, and director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.

WFH Guidelines for the Management of Hemophilia, 3rd edition

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Statins and the COVID-19 main protease: in silico evidence on direct interaction
Archives of Medical Science; Reiner Z

Apr 24th, 2020 - No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COV...

Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations
Journal of Biomolecular Structure and Dynamics;

The new Corona-virus, recently called the severe acute respiratory syndrome Coronavirus (SARS-CoV-2) appears for the first time in China and more precisely in Wuhan (December 2019). This disease can be fatal. Seniors, and people with other medical conditions (diabetes, heart disease…), may be more vulnerable and become seriously ill. This is why research into drugs to treat this infection remai...

Small Molecule Inhibitors in the Treatment of Rheumatoid Arthritis and Beyond: Latest Updates and Potential Strategy for Fighting COVID-19
Cells Massalska M

Aug 10th, 2020 - The development of biological disease-modifying antirheumatic drugs (bDMARDs) and target synthetic DMARDs (tsDMARDs), also known as small molecule inhibitors, represent a breakthrough in rheumatoid arthritis (RA) treatment. The tsDMARDs are a large family of small molecules targeting mostly the several types of kinases, which are essential in downstream signaling of pro-inflammatory molecules. ...

Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment
Obesity Medicine; Pang J, Liu M et. al.

Jan 5th, 2021 - COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those with obesity, type 2 diabetes (T2D) or cardiovascular diseases (CVD). Extra cautions are needed in the treatment of those patients.

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Science White KM, Rosales R et. al.

Jan 24th, 2021 - SARS-CoV-2 viral proteins interact with the eukaryotic translation machinery and inhibitors of translation have potent antiviral effects. Here we report that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (IC90 = 0.88 nM) 27.5-fold more potent than remdesivir against SARS-CoV-2 in vitro, with limited toxicity in cell culture.

Investigational multitargeted kinase inhibitors in development for head and neck neoplasms

Feb 11th, 2019 - Despite advances in treatment, head and neck squamous cell carcinoma (HNSCC) survival rates remain stagnant. Current treatment is associated with significant toxicities and includes chemotherapy, radiation, surgery and few targeted treatments. Targeted treatments, epidermal growth factor receptor (EGFR)-targeted agent, cetuximab, and immune checkpoint inhibitors, pembrolizumab and nivolumab, sh...

HEMLIBRA® (emicizumab-kxwh)

Discover FDA approved HEMLIBRA® (emicizumab-kxwh) for prophylactic treatment in Hemophilia A patients with or without factor VIII inhibitors. See BOXED WARNING.

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
The New England Journal of Medicine;

Jun 12th, 2019 - Myocarditis after the use of immune checkpoint inhibitors is a potentially fatal complication. Immune suppression with glucocorticoids is often effective once the problem is identified. In a patient with glucocorticoid-refractory disease, use of alemtuzumab rapidly reversed the myocarditis and led to complete recovery without infection.

Phosphodiesterase 5 inhibitors for pulmonary hypertension
Barnes,H.,et al

Jan 30th, 2019 - Pulmonary hypertension (PH) comprises a group of complex and heterogenous conditions, characterised by elevated pulmonary artery pressure, and which left untreated leads to right‐heart failure and death. PH includes World Health Organisation (WHO) Group 1 pulmonary arterial hypertension (PAH); Group 2 consists of PH due to left‐heart disease (PH‐LHD); Group 3 comprises PH as a result of lung di...

Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
Open Access Rheumatology; D'Angelo,S.,et al

Mar 1st, 2017 - Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease with a broad clinical spectrum and variable course. It can involve musculoskeletal structures as well as skin, nails, eyes, and gut. The management of PsA has changed tremendously in the last decade, thanks to an earlier diagnosis, an advancement in pharmacological therapies, and a wider application of a multidisciplinary...

Effect of acetazolamide on visual function in patients with idiopathic intracranial hyp...
JAMA , Wall M et. al.

Apr 23rd, 2014 - Acetazolamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficient information to establish an evidence base for its use. To determine whether acetazolamide is beneficial in improving vision when added to a low-sodium weight reduction diet in patients with IIH and mild visual loss. Multicenter, randomized, double-masked, placebo-controlled study of ace...

Rosuvastatin for sepsis-associated acute respiratory distress syndrome.
The New England Journal of Medicine; , Truwit JD et. al.

May 19th, 2014 - In the acute respiratory distress syndrome (ARDS), inflammation in the lungs and other organs can cause life-threatening organ failure. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) can modulate inflammatory responses. Previous observational studies suggested that statins improved clinical outcomes in patients with sepsis. We hypothesized that rosuvastatin therapy woul...

Antidepressant use in pregnancy and the risk of cardiac defects.
The New England Journal of Medicine; Huybrechts KF, Palmsten K et. al.

Jun 18th, 2014 - Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and other antidepressants during pregnancy is associated with an increased risk of congenital cardiac defects is uncertain. In particular, there are concerns about a possible association between paroxetine use and right ventricular outflow tract obstruction and between sertraline use and ventricular septal defects. We performed ...

Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized c...
JAMA Psychiatry; LaFrance WC, Baird GL et. al.

Jul 5th, 2014 - There is a paucity of controlled treatment trials for the treatment of conversion disorder, seizures type, also known as psychogenic nonepileptic seizures (PNES). Psychogenic nonepileptic seizures, the most common conversion disorder, are as disabling as epilepsy and are not adequately addressed or treated by mental health clinicians. To evaluate different PNES treatments compared with standard...

Inhibition of the mTORC pathway in the antiphospholipid syndrome.
The New England Journal of Medicine; Canaud G, Bienaimé F et. al.

Jul 23rd, 2014 - Although thrombosis is considered the cardinal feature of the antiphospholipid syndrome, chronic vascular lesions are common, particularly in patients with life-threatening complications. In patients who require transplantation, vascular lesions often recur. The molecular pathways involved in the vasculopathy of the antiphospholipid syndrome are unknown, and adequate therapies are lacking. We u...